Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STATION: Neoadjuvant SBRT, Tislelizumab, and Anlotinib in Resectable NSCLC
NCT07231575Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07231575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231575.